Green Cross Flu Vaccine Obtains Taiwan Approval Through Technology Transfer

GC Green Cross's influenza vaccine 'GC Flu Quadrivalent'
Photo by GC Green Cross

GC Green Cross recently announced on the 13th that the quadrivalent influenza vaccine of Medigen Vaccine Biologics Corp. (MVC), a Taiwanese vaccine specialist company that received the influenza vaccine manufacturing technology from GC Green Cross, has obtained product approval from the Taiwan Food and Drug Administration.

GC Green Cross explained that it formed a technology transfer partnership with MVC in 2018 and demonstrated immunogenicity and safety equivalent to the comparator drug through local clinical trials. With this approval, GC Green Cross will supply influenza vaccine bulk to MVC, and MVC will receive the vaccine finished product manufacturing technology from GC Green Cross to establish a local production system. The influenza vaccine market in Taiwan is known to be worth 50 million USD (approximately 66.2 billion KRW).

GC Green Cross plans to accelerate vaccine production localization and expand its global influenza vaccine market share by using this entry into the Taiwanese market as a stepping stone. Heeun Chul Hur, CEO of GC Green Cross, said, “Our goal is to build a global vaccine infrastructure based on the strong vaccine technology accumulated over half a century.”